Serum predictive marker related to diagnosis of gestational hypertension disease

Abstract

The invention provides a predictive marker related to the onset risk of gestational hypertension, namely early pregnancy serum BDNF, and provides application of the marker in preparation of an auxiliary diagnosis reagent for gestational hypertension. Besides, by constructing a logistic regression model, a model for predicting the hypertensive disorder in pregnancy and various subtypes thereof according to the markers is obtained, the prediction model is rapid, convenient, high in accuracy and reasonable and feasible in design, and a theoretical basis is provided for early prediction and prevention and treatment of HDP disease progression, so that high-risk groups are found and strictly managed as soon as possible, and the development of the hypertensive disorder in pregnancy is promoted. The composition can relieve illness conditions, prolong gestational weeks, improve prognosis and finally reduce the mortality rate of mothers and babies.

Description

technical field [0001] The invention belongs to the medical field, and particularly relates to serum predictive biomarkers related to the diagnosis of hypertensive disorders in pregnancy and applications thereof. Background technique [0002] Hypertensive disorders of pregnancy (HDP) are a group of diseases that coexist with pregnancy and elevated blood pressure, and are the main cause of maternal and perinatal morbidity and mortality worldwide, accounting for 2% to 10%. It threatens maternal and infant health, and often leads to poor maternal and infant outcomes. Currently, it is the third leading cause of maternal death in my country after postpartum hemorrhage and amniotic fluid embolism. In addition, HDP pregnant women are at increased risk of developing cardiovascular diseases in the future, including hypertension, atherosclerosis, coronary heart disease, heart failure, etc. The risk is 2-8 times higher than that of pregnant women with normal blood pressure during pregna...

AI Technical Summary

Problems solved by technology

However, there is currently no recognized effective method for predicting HDP and its various disease subtypes

Independent maternal history or a single biophysical indicator is of low value in predicting hypertensive disorders during pregnancy, and multi-indicator joint prediction is advocated. There are many influencing factors for hypertensive disorders during pregnancy. Clinical risk factors such as obesity, diabetes, primiparous women, multiple pregnancy, high baseline blood pressure before pregnancy, and rapid weight gain during pregnancy; in addition, there are many biomarkers such as pregnancy-associated serum protein A (PAPP-A), activin A. Maternal serological indicators such as placental growth factor, AFP, soluble endothelial factor, and β-hCG are also used in the prediction of HDP, with a wide range of predictive values ​​and different gestational weeks

Therefore, there is an urgent need for effective prediction methods to identify high-risk pregnant women in early pregnancy and carry out early prevention. Many researchers mostly obtain some new early prediction biological indicators from the results of etiology research to carry out early prediction research. So far There are no recognized and unified indicators and methods that are really used to guide clinical work

Images